Co-founder Joost Holthuis replaces founder as chief executive amid $7 million financing round

15 December 2014

The co-founder of Dutch nanomedicine company Cristal Therapeutics, Joost Holthuis, has succeeded its founder Cristianne Rijcken as chief executive of the company.

He has extensive experience in the biotech field and founded OctoPlus, as well as serving on the boards of various startups and being a venture partner at biotech venture capital investor BioGeneration, also in the Netherlands.

Dr Rijcken has been chief executive since the company’s incorporation in 2011, and will become chief scientific officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >